Charles Schwab Investment Management Inc Galectin Therapeutics Inc Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 65,073 shares of GALT stock, worth $56,613. This represents 0.0% of its overall portfolio holdings.
Number of Shares
65,073
Previous 65,073
-0.0%
Holding current value
$56,613
Previous $147,000
21.09%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding GALT
# of Institutions
91Shares Held
9.65MCall Options Held
1.16MPut Options Held
1.98M-
Vanguard Group Inc Valley Forge, PA2.13MShares$1.86 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$1.36 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.18MShares$1.03 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA863KShares$750,4110.0% of portfolio
-
Commonwealth Equity Services, LLC483KShares$420,4390.0% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $51.7M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...